Showing results (171-180 of 431) with videos related to

Sort By:
Pageof 44
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2022
Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B)James Chih-Hsin Yang, Yuichiro Ohe, Chao-Hua Chiu, et al.
Thoracic Cancer|February 21, 2020
Number of metastatic organs negatively affects the treatment sequence in patients with EGFR-TKI failureTakaaki Mizuno, Hidehito Horinouchi, Sho Watanabe, et al.
Translational Lung Cancer Research|August 14, 2023
Distinct metastatic spread and progression patterns in patients treated with crizotinib for ROS1- and ALK-rearranged non-small cell lung cancer: a single-center retrospective studyTomoaki Nakamura, Tatsuya Yoshida, Yuki Takeyasu, et al.
Anticancer Research|December 3, 2024
Key Therapeutic Agents for Thymic Carcinoma in Real-world Clinical PracticeAkiko Tateishi, Yusuke Okuma, Yasushi Goto, et al.
European Journal of Cancer (Oxford, England : 1990)|October 11, 2020
Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancerMasayuki Shirasawa, Tatsuya Yoshida, Yuji Matsumoto, et al.
Clinical Lung Cancer|June 7, 2017
Comparison of Radiotherapy and Chemoradiotherapy for Locoregional Recurrence of Non-small-cell Lung Cancer Developing After SurgeryShinji Nakamichi, Hidehito Horinouchi, Tetsuhiko Asao, et al.
International Journal of Clinical Pharmacology and Therapeutics|December 23, 2020
Exacerbation of atrioventricular block associated with concomitant use of amlodipine and aprepitant in a lung cancer patient: A case reportHideyuki Hibino, Yoshinori Makino, Naomi Sakiyama, et al.
Clinical Lung Cancer|November 22, 2016
Comparison of Amrubicin and Weekly Cisplatin/Etoposide/Irinotecan in Patients With Relapsed Small-cell Lung CancerHitomi Sumiyoshi Okuma, Hidehito Horinouchi, Shinsuke Kitahara, et al.
International Journal of Clinical Oncology|August 27, 2024
A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutationsKiyotaka Yoh, Koichi Azuma, Hidetoshi Hayashi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 10, 2007
Proteomic signature corresponding to the response to gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinomaTetsuya Okano, Tadashi Kondo, Kiyonaga Fujii, et al.
Pageof 44